|Dr. David Alan Campbell Ph.D.||Pres, CEO & Director||688.58k||N/A||1960|
|Dr. Shahram Salek-Ardakani Ph.D.||Chief Scientific Officer||371.21k||N/A||1974|
|Dr. Wayne Godfrey M.D.||Chief Medical Officer||488.39k||N/A||1961|
|Mr. Tighe M. Reardon C.F.A., CPA, CPA||Acting Chief Financial Officer||N/A||N/A||1977|
|Mr. Tommy Diraimondo Ph.D.||Director of Research||N/A||N/A||N/A|
|Mr. Andy Hollman Meyer||Chief Bus. Officer||N/A||N/A||1984|
|Mr. Charles M. Winter||Sr. VP of Chemistry, Manufacturing & Controls||N/A||N/A||N/A|
|Mr. Byron Robinson J.D., Ph.D.||Chief Strategy Officer||N/A||N/A||1965|
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Janux Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.